Both dynorphin A1-17 and [des-tyr1]dynorphin A2-17 inhibit adenylyl cyclase activity in rat caudate putamen

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 1, 1996, Pages 359-365

  Claye, Lynne H ^a   Unterwald, Ellen M ^a   Ho, Ann ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; DYNORPHIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE; PEPTIDE FRAGMENT; COCAINE; DYNORPHIN A; DYNORPHIN A DERIVATIVE; DYNORPHIN[1-13]; DYNORPHIN[1-6]; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NORBINALTORPHIMINE;

ANIMAL; ARTICLE; CAUDATE NUCLEUS; DRUG ANTAGONISM; ENZYMOLOGY; FISCHER 344 RAT; MALE; PHYSIOLOGY; PUTAMEN; RAT; ANIMAL TISSUE; CONTROLLED STUDY; DRUG TOLERANCE; DRUG TRANSFORMATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RECEPTOR DENSITY; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ANIMALS; CAUDATE NUCLEUS; DYNORPHINS; MALE; NALOXONE; PEPTIDE FRAGMENTS; PUTAMEN; RATS; RATS, INBRED F344; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0030302112     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. ACETO, M. D., DEWEY, W. L., CHANG, J.-K. AND LEE, N. M.: Dynorphin-(1-13): Effects in non tolerant and morphine-dependent rhesus monkeys. Eur. J. Pharmacol. 83: 139-142, 1982.
2. ATTALI, B., SAYA, D. AND VOGEL, Z.: Kappa-opiate agonists inhibit adenylate cyclase and produce heterologous desensitization in rat spinal cord. J. Neurochem. 52: 360-364, 1989.
3. BAKSHI, R. AND FADEN, A. I.: Blockade of the glycine modulatory site of NMDA receptors modifies dynorphin-induced behavioral effects. Neurosci. Lett. 110: 113-117, 1990a.
4. BAKSHI, R. AND FADEN, A. I.: Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis. Brain Res. 507: 1-5, 1990b.
5. BAKSHI, R., NI, R.-X. AND FADEN, A. I.: N-methyl-d-aspartate (NMDA) and opioid receptors mediate dynorphin-induced spinal cord injury: Behavioral and histological studies. Brain Res. 580: 255-264, 1992.
6. BODNER, G., PINTO, S., ALBECK, H. AND KREEK, M. J.: Effects of dynorphin peptides on human natural killer cell activity in vitro. In Problems of Drug Dependence, 1991: Proceedings of the 53rd Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Palm Beach, FL, National Institute on Drug Abuse Research Monograph Series, ed. by L. S. Harris, 119: 331, 1992.
7. BROWN, B. L., ALBANO, J. D. M., ELKINS, R. P., SGHERZI, A. M. AND TAMPION, W.: A simple and sensitive saturation assay method for measurement of adenosine 3′,5′-cyclic monophosphate. Biochem. J. 121: 561-562, 1971.
8. BUTELMAN, E. R., YU, J., CHOU, J., CHAIT, B T., KREEK, M. J. AND WOODS, J. H.: Dynorphin A (1-13): Biotransformation in human and rhesus monkey blood and antinociception. In. Problems of Drug Dependence, 1995: Proceedings of the 57th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Scottsdale, AZ, National Institute on Drug Abuse Research Monograph Series, ed. by L. S. Harris, in press, 1996.
9. 2 Opioid receptors inhibit NMDA receptor-mediated synaptic currents in guinea pig ca3 pyramidal cells. J. Neurosci. 14: 5580-5589, 1994.
10. CAVICCHINI, E., CANDELETTI, S., SPAMPINATO, S. AND FERRI, S.: Hypothermia elicited by some prodynorphin-derived peptides: Opioid and non-opioid actions Neuropeptides 14: 45-50, 1989.
11. CHAVKIN, C. AND GOLDSTEIN, A.: Specific receptor for the opioid peptide dynorphin: Structure-activity relationships. Proc. Natl. Acad. Sci. U.S.A. 78: 6543-6547, 1981.
12. CHEN, Y., MESTEK, A., LIU, J. AND YU, L : Molecular cloning of rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem. J. 295: 625-628, 1993.
13. CHOU, J. Z., CHAIT, B. T., WANG, R. AND KREEK, M. J.: Study of dynorphin A peptides in vitro processing in human blood by matix-assisted laser desorption mass spectrometry. In Problems of Drug Dependence, 1994: Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Palm Beach, FL, National Institute on Drug Abuse Research Monograph Series, ed. by L. S. Harris, 153: 252, 1995.
14. CHOU, J. Z., KREEK, M. J. AND CHAIT, B. T.: Matrix-assisted laser desorption mass spectrometry of biotransformation products of dynorphin A in vitro. J. Am. Soc. Mass Spectro. 5: 10-16, 1994a.
15. CHOU, J. Z., KREEK, M. J. AND CHAIT, B. T.: Matrix-assisted laser desorption mass spectrometry of neuropeptides. In Proceedings of the 40th ASMS Conference on Mass Spectrometry and Allied Topics, p. 307, Washington, DC, May 31-June 5, 1992.
16. CHOU, J. Z., MAISONNEUVE, I. M., CHAIT, B. T. AND KREEK, M. J.: Study of dynorphin A (1-17) in vivo processing in rat brain by microdialysis and matrix-assisted laser desorption mass spectrometry. In Problems of Drug Dependence, 1993: Proceeding of the 55th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Toronto, Canada, National Institute on Drug Abuse Research Monograph Series, ed. by L. S. Harris, 141: 240, 1994b.
17. CHOU, J. Z., PINTO, S., KREEK, M. J. AND CHATI, B. T.: Study of opioid peptides by laser desorption mass spectrometry. In Problems of Drug Dependence, 1992: Proceeding of the 54th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Keystone, CO, National Institute on Drug Abuse Research Monograph Series, ed. by L. S. Harris, 132: 380, 1993.
18. CODD, E. E., ALOYO, V. J. AND WALKER, R. F.: A non-opioid pattern characterizes inhibition of growth hormone releasing peptide binding by dynorphin-related peptides. Neuropeptides 15: 133-137, 1990.
19. COX, B. M., OPHEIM, K. E., TESCHEMACHER, H. AND GOLDSTEIN, A.: A peptide-like substance from pituitary that acts like morphine. 2. Purification and properties. Life Sci. 16: 1777-1782, 1975.
20. CULPEPPER-MORGAN, J. A., HOLT, P. R. AND KREEK, M. J.: Measurement of relative mu, kappa, and delta opioid receptor subtype densities in guinea pig colon. Clin. Res. 35: 407A, 1987.
21. CULPEPPER-MORGAN, J. A., HOLT, P. R., LAROCHE, D. AND KREEK, M. J.: Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig. Life Sci. 56: 1187-1192, 1995.
22. CULPEPPER-MORGAN, J. A., KREEK, M. J., HOLT, P. R., LAROCHE, D., ZHANG, J. AND O'BRYAN, L.: Orally administered kappa as well as mu opiate agonists delay gastrointestinal transit time in the guinea pig. Life Sci. 42: 2073-2077, 1988.
23. ERIKSSON, P. S., HANSSON, E. AND RONNBACK, L.: δ And κ opiate receptors in primary astroglial cultures from rat cerebral cortex. Biochem. Res. 15: 1123-1126, 1990.
24. FADEN, A. I.: Opioid and nonopioid mechanisms may contribute to dynorphin's pathophysiological actions in spinal cord injury. Ann. Neurol. 27: 67-74, 1990.
25. FADEN, A. I. AND JACOBS, T. P.: Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action. Br. J. Pharmacol. 81: 271-276, 1984.
26. FRIEDERICH, M. W., FRIEDERICH, D. P. AND WALKER, J. M.: Effects of dynorphin (1-8) on movement: Non-opiate effects and structure-activity relationship. Peptides 8: 837-840, 1987.
27. FRIEDMAN, H. J., JEN, M.-F., CHANG, J. K., LEE, N. M. AND LOH, H. H.: Dynorphin: A possible modulatory peptide on morphine or β-endorphin analgesia in mouse. Eur. J. Pharmacol. 69: 357-360, 1981.
28. GOLDSTEIN, A., FISCHLI, W., LOWNEY, L. I., HUNKAPILLER, M. AND HOOD, L.: Porcine pituitary dynorphin: Complete amino acid sequence of the biologically active heptadecapeptide. Proc. Natl. Acad. Sci. U.S.A. 78: 7219-7223, 1981.
29. GOLDSTEIN, A., TACHIBANA, S., LOWNEY, L. I., HUNKAPILLER, M. AND HOOD, L.: Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. U.S.A. 76: 6666-6670, 1979.
30. HERMAN, B. H. AND GOLDSTEIN, A.: Antinociception and paralysis induced by intrathecal dynorphin-A. J. Pharmacol. Exp. Ther. 232: 27-32, 1985.
31. HOOKE, L. P. AND LEE, N. M.: [Des-Tyrl]Dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay. J. Pharmacol. Exp. Ther 273: 802-807, 1995.
32. IZENWASSER, S., BUZAS, B. AND COX, B. M., Differential regulation of adenylyl cyclase activity by mu- and delta-opioids in rat caudate putamen and nucleus accumbens. J. Pharmacol. Exp. Ther. 267: 145-152, 1993.
33. JAMES, I., FISCHLI, W. AND GOLDSTEIN, A.: Opioid receptor selectivity of dynorphin gene products. J. Pharmacol. Exp. Ther. 228: 88-93, 1984.
34. KAKIDANI, H., FURUTANI, Y., TAKAHASHI, H., NODA, M., MORIMOTO, T., HIROSE, T., ASAI, M., INAYAMA, S., NAKANISHI, S. AND NUMA, S.: Cloning and sequence analysis of cDNA for porcine β-neo-endorphin/dynorphin precursor. Nature (Lond.) 289: 245-249, 1982.
35. KATO, Y., MATSUHITA, N., KATAKAMI, H., SHIMATSU, A. AND IMURA, H.: Stimulation by dynorphin of prolactin and growth hormone secretion in the rat. Eur. J. Pharmacol. 73: 353-355, 1981.
36. KONKOY, C. S. AND CHILDERS, S. R : Dynorphin-selective inhibition of adenylyl cyclase in guinea pig cerebellum membranes. Mol. Pharmacol. 36: 627-633, 1989.
37. KRULICH, L., KOENIG, J. I., CONWAY, S., MCCANN, S. M. AND MAYFIELD, M. A.: Opioid κ receptors and the secretion of prolactin (PRL) and growth hormone in the rat. Neuroendocrinology 42: 75-81, 1986.
38. LAWRENCE, D. M. P. AND BIDLACK, J. M.: A kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein. J. Pharmacol. Exp. Ther. 266: 1678-1683, 1993.
39. LOWNEY, L. I., GENTLEMAN, S. B. AND GOLDSTEIN, A.: A pituitary endorphin with novel properties. Life Sci. 24: 2377-2384, 1979.
40. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
41. MANSOUR, A., FOX, C. A., AKIL, H. AND WATSON, S. J.: Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications Trends Neurosci. 18: 22-29, 1995
42. 1 Receptor mRNA distribution in the rat CNS: Comparison to κ receptor binding and prodynorphin mRNA. Mol. Cell. Neurosci. 5: 124-144, 1994.
43. MASSARDIER, D. AND HUNT, P. F.: A direct non-opiate interaction of dynorphin-(1-13) with the N-methyl-D-aspartate (NMDA) receptor. Eur. J. Pharmacol. 170: 125-126, 1989.
44. MAURER, R.: Multiplicity of opiate receptors in different species. Neurosci. Lett. 30: 303-307, 1982.
45. REID, M. S., HERRERA-MARSCHITZ, M., HOKFELT, T., LINDEFORS, N., PERSSON, H. AND UNGERSTEDT, U.: Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: Evidence for direct regulatory mechanisms. Exp. Brain Res. 82: 293-303, 1990.
46. SHARMA, S. K., KLEE, W. A. AND NIREMBERG, M.: Opiate dependent modulation of adenylate cyclase activity. Proc. Natl. Acad. Sci. U.S.A. 74: 3365-3369, 1977.
47. SHUKLA, V. K., BANSINATH, M., DUMONT, M. AND LEMAIRE, S.: Selective involvement of kappa opioid and phencyclidine receptors in the analgesic and motor effects of dynorphin-A-(1-13)-Tyr-Leu-Phe-Asn-Gly-Pro. Brain Res. 591: 176-180, 1992.
48. SHUKLA, V. K. AND LEMAIRE, S.: Non-opioid effects of dynorphins: Possible role of the NMDA receptor. Trends Pharmacol. Sci. 15: 420-424, 1994.
49. SHUKLA, V. K., LEMAIRE, S. AND DUMONT, M.: Central non-opioid motor effects of dynorphins: Antagonism by NMDA receptor antagonists. Soc. Neurosci. Abstr. 20: 1351, 1994.
50. SPANAGEL, R., HERZ, A. AND SHIPPENBERG, T.: The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study. J. Neurochem. 55: 1734-1740, 1990.
51. SPANGLER, R., UNTERWALD, E. M. AND KREEK, M. J.: Binge cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudateputamen. Mol. Brain Res. 19: 323-327, 1993.
52. SPANGLER, R., ZHOU, Y , UNTERWALD, E., YUFEROV, V., HO, A. AND KREEK, M. J.: Opioid peptide and receptor mRNA levels in the rat brain determined by TCA Precipitation of mRNA: cRNA hybrids. In: Problems of Drug Dependence, 1995: Proceedings of the 57th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Scottsdale, AZ, National Institute on Drug Abuse Research Monograph Series, ed. by L. S. Harris, in press, 1996.
53. TAKEMORI, A. E., HO, B. Y., NAESETH, J. S. AND PORTOGHESE, P. S.: Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp Ther. 246: 255-258, 1988.
54. TAKEMORI, A. E., LOH, H. H. AND LEE, N. M : Suppression by dynorphin A-(1-13)of the expression of opiate withdrawal and tolerance in mice. Eur. J. Pharmacol. 221: 223-226, 1992.
55. 1]dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J. Pharmacol. Exp. Ther. 266: 121-124, 1993.
56. TAVANI, A., GAMBINO, M. C. AND PETRILLO, P.: The opioid kappa-selective compound U-50,488H does not inhibit intestinal propulsion in rats. J. Pharm. Pharmacol. 36: 343-344, 1984.
57. TULUNAY, F. C., JEN, M.-F., CHANG, J.-K., LOH, H. H. AND LEE, N. M.: Possible regulatory role of dynorphin on morphine- and β-endorphin-induced analgesia. J. Pharmacol. Exp. Ther. 219: 296-298, 1981.
58. UNTERWALD, E. M., COX, B. M., KREEK, M. J., COTE, T. E. AND IZENWASSER, S.: Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity. Synapse 15: 33-38, 1993.
59. 2 opioid receptors in rat and guinea pig brain. Brain Res. 562: 57-65, 1991.
60. UNTERWALD, E. M., RUBENFELD, J. M. AND KREEK, M. J.: Repeated cocaine administration upregulates κ and μ, but not δ opioid receptors. NeuroReport 5: 1613-1616, 1994.
61. WALKER, J. M., MOISES, H. C., COY, D. H., BALDRIGHI, G. AND AKIL, H.: Nonopiate effects of dynorphin and des-tyr-dynorphin. Science (Wash. DC) 218: 1136-1138, 1982a.
62. WALKER, J. M., TUCKER, D. E., COY, D. H., WALKER, B. B. AND Am., H.: Destyrosine-dynorphin antagonizes morphine analgesia. Eur. J. Pharmacol. 85: 121-122, 1982b.
63. WEN, H. L. AND HO, W. K. K.: Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur. J. Pharmacol. 82: 183-186, 1982.
64. WEN, H. L., HO, W. K. AND WEN, P. Y.: Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur. J. Pharmacol. 100: 155-162, 1984.
65. WINER, B. J.: Statistical Principles in Experimental Design, 2nd ed., p. 497. McGraw Hill, New York, 1971.
66. XIE, G.-X., MENG, F., MANSOUR, A., THOMPSON, R. C., HOVERSTEN, M. T., GOLDSTEW, A., WATSON, S. J. AND AKIL, H.: Primary structure and functional expression of a guinea pig κ opioid (dynorphin) receptor. Proc Natl. Acad. Sci. U.S.A. 91: 3779-3783, 1994.
67. XUE, J.-C., CHEN, C., ZHU, J., KUNAPULI, S., DERIEL, J. K., YU, L. AND CHEN, L.-Y. L.: Differential binding domains of peptide and non-peptide ligands in the cloned rat κ opioid receptor. J. Biol. Chem. 269: 30195-30199, 1994.
68. 3H]Dynorphin A biding and κ selectivity of prodynorphin peptides in rat, guinea pig and monkey brain. Eur. J. Pharmacol. 121: 355-365, 1986.
69. YU, J., BUTELMAN, E. R., WOODS, J. H., CHAIT, B. Y. AND KREEK, M. J.: Studies of in vitro processing of dynorphin A (1-17) in human blood and in rhesus monkey blood. In: Problems of Drug Dependence, 1995: Proceedings of the 57th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Scottsdale, AZ, National Institute on Drug Abuse Research Monograph Series, ed. by L. S. Harris, in press, 1996.
70. YU, V. C., RICHARDS, M. L. AND SADEE, W.: A human neuroblastoma cell line expresses mu and delta opiate receptor sites. J. Biol. Chem. 261:1065-1070, 1986.
71. 2 opioid receptors. Proc. Natl. Acad. Sci. U.S.A. 85: 4061-4065, 1988.